- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02015494
Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention
March 5, 2015 updated by: VaxInnate Corporation
Phase 1 Study of the Safety and Immunogenicity of VAX2012Q: A Quadrivalent Influenza Vaccine in Healthy Adults Age 18-40 Years
One dose of escalating strengths of an investigational influenza vaccine VAX2012Q (Quadrivalent Recombinant Hemagglutinin Seasonal Influenza Vaccine) will be evaluated for tolerability and immunogenicity in healthy adults 18-40 years of age.
Study Overview
Detailed Description
This is a multi-center, open-label, dose escalating study in which up to 320 healthy subjects age 18-40 years will be administered VAX2012Q at one of up to 7 dose levels.
VAX2012Q vaccine will be formulated at the clinical site ("field mix") from the four components (VAX128C, VAX181, VAX173 and VAX172) in diluent to produce ten doses in a multi-dose vial for use within 12 hours of preparation.
The dose will be prepared from appropriate dilutions from the monovalent drug product vials.
Data for safety and immunogenicity will be collected after each dose with safety being assessed after each dose level and immune response, after dose level 4. Reactogenicity and safety labs through Day 1 will be reviewed by the Safety Monitoring Committee (SMC) prior to enrolling in the next dose level.
Study Type
Interventional
Enrollment (Actual)
316
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kansas
-
Lenexa, Kansas, United States, 66219
- Johnson County Clin-Trials
-
-
New York
-
Rochester, New York, United States, 14609
- Rochester Clinical Research, Inc
-
-
South Carolina
-
Mt. Pleasant, South Carolina, United States, 29464
- Coastal Carolina Research Center
-
-
Texas
-
Austin, Texas, United States, 78745
- Tekton Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females aged 18-40 years of age at the time of vaccination in good health as determined by medical history, physical exam, laboratory assessments and the clinical judgment of the Principal Investigator
- Able to provide informed consent indicating that they understand the purpose of this study and are willing to adhere to the procedures described in this protocol
- If the subject is a female of childbearing potential, she must use adequate contraceptive precautions (e.g., intrauterine contraceptive device, oral contraceptives or other equivalent hormonal contraception) for 2 months prior to vaccination and continue to use such precautions for a minimum of three months after vaccination. She must also have a negative urine pregnancy test within 24 hours prior to receiving study vaccine. Women at least one year post-menopausal or surgically sterile will not be considered of childbearing potential.
- Willing to receive the unlicensed vaccine given as an IM injection
- Willing to provide multiple blood specimens collected by venipuncture
Exclusion Criteria:
- Use of any investigational or non-registered drug or vaccine product within 30 days preceding the administration of the study vaccine or planned use within the first six weeks of the study period
- Has received any licensed or other investigational influenza vaccine within 3 months prior to enrollment in this study or expected receipt of any influenza vaccination before the Day 21 blood collection
- History of excessive alcohol use, drug abuse or significant psychiatric illness
- Tobacco use within 3 months of enrollment and throughout first 6 months of the study
- Has a chronic illness (e.g., liver or kidney disease), receiving a concomitant therapy or have any other condition that could interfere with the subject's participation in the study or in the interpretation of the study results
- Clinically significant abnormal liver function tests at screening
- Positive serology for HBsAg, HCV or HIV antibodies
- Pregnant or lactating female
- Having cancer or have received treatment for cancer within three years (persons with a history of cancer who are disease-free without treatment for three years or more are eligible), excluding minor skin cancers, which are allowed unless located at the vaccination site
- Persons with impaired immune responsiveness (of any cause), including diabetes mellitus and autoimmune disorders
- Persons presently receiving or having a recent history of receiving (within the past six months) any medication or therapeutic modality that affects the immune system such as allergy shots, immune globulin, interferon, immunomodulators, radiation therapy, cytotoxic drugs or drugs known to be frequently associated with significant major organ toxicity, or systemic corticosteroids (oral or injectable). Inhaled and topical corticosteroids are allowed.
- Persons with a history of severe allergic reaction after previous vaccinations or hypersensitivity to any seasonal influenza vaccine component
- Persons with a history of Guillain-Barré Syndrome
- Receipt of blood or blood products 8 weeks prior to vaccination or planned administration during the three week study period following vaccination
- Donation of blood or blood products within 8 weeks prior to vaccination or during the three week study period following
- An oral temperature >100.4° or acute disease within 72 hours prior to vaccination, defined as the presence of a moderate or severe illness (as determined by the investigator through medical history and physical examination; for example, those requiring an absence from work) with or without fever.
- Body Mass Index >29.9
- Any disorder of coagulation
- A clinical diagnosis of influenza within the previous 12 months
- Any other condition or circumstance which, in the opinion of the Principal Investigator, poses an unacceptable risk for participation in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 4 mcg VAX2012Q
|
Recombinant influenza HA vaccine delivered IM
Other Names:
|
Experimental: 8 mcg VAX2012Q
|
Recombinant influenza HA vaccine delivered IM
Other Names:
|
Experimental: 14 mcg VAX2012Q
|
Recombinant influenza HA vaccine delivered IM
Other Names:
|
Experimental: 18 mcg VAX2012Q
|
Recombinant influenza HA vaccine delivered IM
Other Names:
|
Experimental: 12 mcg VAX2012Q
|
Recombinant influenza HA vaccine delivered IM
Other Names:
|
Experimental: 8 mcg VAX2012Q repeated
8 mcg VAX2012Q
|
Recombinant influenza HA vaccine delivered IM
Other Names:
|
Experimental: 12 mcg VAX2012Q repeated
12 mcg VAX2012Q
|
Recombinant influenza HA vaccine delivered IM
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: 21 Days
|
Injection site and systemic symptoms will be collected for 21 days after vaccination.
Other AEs assessed as related to vaccination will be collected at a 6 month clinic visit and a 1 year phone call.
|
21 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity
Time Frame: 21 days and 6 months post-vaccination
|
Immune response to vaccine will be measured by serum HAI levels
|
21 days and 6 months post-vaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: C. Jo White, MD, VaxInnate Corporation
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, Ozer K, Tussey L, Shaw A. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine. 2011 Jul 12;29(31):4897-902. doi: 10.1016/j.vaccine.2011.05.001. Epub 2011 May 17.
- Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, Fitzgerald T, Liu G, Kavita U, Song L, Dark I, Shaw A. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine. 2010 Dec 6;28(52):8268-74. doi: 10.1016/j.vaccine.2010.10.009. Epub 2010 Oct 20.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2014
Primary Completion (Actual)
December 1, 2014
Study Completion (Anticipated)
December 1, 2015
Study Registration Dates
First Submitted
December 9, 2013
First Submitted That Met QC Criteria
December 12, 2013
First Posted (Estimate)
December 19, 2013
Study Record Updates
Last Update Posted (Estimate)
March 6, 2015
Last Update Submitted That Met QC Criteria
March 5, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VAX2012Q-01
- BARDA (Other Grant/Funding Number: HHSO10020110011C)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
NPO PetrovaxCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Acute Respiratory Infection | Influenza Type B | Flu | Influenza A H3N2 | Influenza A H1N1 | Flu, Human | Influenza EpidemicRussian Federation
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
Clinical Trials on VAX2012Q
-
VaxInnate CorporationUnknown
-
VaxInnate CorporationDepartment of Health and Human Services; AccelovanceUnknown